SynthesisBMC nephrology2025
Efficacy and safety of tacrolimus in the treatment of Henoch-Schönlein purpura nephritis: systematic review and meta-analysis.
Synthesis in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Telitacicept for childhood HSPN: A prospective self-controlled study.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHenoch-Schönlein purpura nephritis (HSPN) is the most severe manifestation of Henoch-Schönlein purpura, significantly impacting patient outcomes. While immunosuppressive therapies like cyclophosphamide (CTX) and mycophenolate mofetil (MMF) are commonly used, evidence regarding the efficacy and safety of tacrolimus (TAC) in HSPN remains limited. This study presents the first systematic review and meta-analysis specifically evaluating the efficacy and safety of tacrolimus (TAC) in treating Henoch-Schönlein purpura nephritis (HSPN), aiming to fill a critical gap in evidence for clinical decision-making.
methodsThis systematic review and meta-analysis, the first focused specifically on TAC in HSPN, included seven studies comprising 727 patients. A comprehensive search was conducted across multiple databases, including the Cochrane Library, PubMed, Embase, Medline, Web of Science, CNKI, Wanfang, SinoMed, VIP, and Embase. Studies comparing TAC with control treatments, such as CTX or MMF, in HSPN patients were included. Odds ratios (ORs) were calculated for dichotomous outcomes, while standardized mean differences (SMDs) with 95% confidence intervals (CIs) were used for continuous variables. Depending on heterogeneity, either random-effects or fixed-effects models were applied. Data synthesis was performed using RevMan software.
resultsA total of seven studies were included. TAC therapy significantly improved clinical efficacy in HSPN patients (OR = 4.43; 95% CI: 2.86-6.87; P < 0.001). Additionally, TAC significantly reduced urine protein levels (SMD = -1.17; 95% CI: -1.83 to -0.51; P < 0.001), serum creatinine (Scr) (SMD = -2.33; 95% CI: -3.00 to -1.65; P < 0.001), and blood urea nitrogen (BUN) (SMD = -1.49; 95% CI: -1.94 to -1.04; P < 0.001). Importantly, there were no significant differences in the incidence of adverse events between the TAC and control groups.
conclusionThis is the first systematic review and meta-analysis specifically evaluating TAC in HSPN, providing novel evidence that TAC is an effective and safe therapeutic option for these patients. Its potential advantages over conventional immunosuppressive therapies highlight the need for further high-quality, long-term randomized controlled trials to confirm these findings and establish TAC's role in HSPN management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.